Alerts will be sent to your verified email
Verify EmailAUROPHARMA
Aurobindo Pharma
|
Alembic Pharma
|
Ipca Laboratories
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
US DMF Filings
|
283.0 . | 132.0 . | 55.0 . |
Europe DMF Filings
|
2001.0 . | n/a | n/a |
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
820.0 . | 257.0 . | 44.0 . |
Number of ANDA's Approved By USFDA
|
672.0 . | 196.0 . | 18.0 . |
R&D as a % of Total Sales
|
5.41 % | 7.0 % | 2.71 % |
Financials
|
|||
5 yr Average ROE
|
15.24 % | 17.53 % | 15.9 % |
5yr average Equity Multiplier
|
1.59 | 1.58 | 1.41 |
5yr Average Asset Turnover Ratio
|
0.72 | 0.79 | 0.81 |
5yr Avg Net Profit Margin
|
13.0 % | 14.0 % | 13.8 % |
Price to Book
|
2.35 | 4.36 | 5.52 |
P/E
|
23.92 | 32.99 | 60.18 |
5yr Avg Cash Conversion Cycle
|
-29.67 Days | 11.4 Days | 74.74 Days |
Inventory Days
|
60.22 Days | 92.17 Days | 100.02 Days |
Days Receivable
|
30.42 Days | 59.84 Days | 55.52 Days |
Days Payable
|
111.73 Days | 198.11 Days | 120.62 Days |
5yr Average Interest Coverage Ratio
|
43.11 | 42.05 | 59.4 |
5yr Avg ROCE
|
18.43 % | 19.16 % | 18.97 % |
5yr Avg Operating Profit Margin
|
20.43 % | 21.64 % | 22.38 % |
5 yr average Debt to Equity
|
0.27 | 0.27 | 0.14 |
5yr CAGR Net Profit
|
-4.01 % | -10.16 % | 1.13 % |
5yr Average Return on Assets
|
9.53 % | 10.9 % | 11.44 % |
Shareholdings
|
|||
Promoter Holding
|
51.83 % | 69.61 % | 46.3 % |
Share Pledged by Promoters
|
20.86 % | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
-0.11 % | 0.13 % | 0.01 % |
Change in Mutual Fund Holding (3 Yrs)
|
8.99 % | 3.48 % | 7.98 % |
Aurobindo Pharma
|
Alembic Pharma
|
Ipca Laboratories
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|